From Guidelines to Bedside: Real-World Insights into Cryoprecipitate Utilization and Appropriateness in High-Volume Clinical Practice

Background: Cryoprecipitate remains a vital blood component in managing bleeding disorders, given its rich content of fibrinogen, factor VIII, von Willebrand factor, and fibronectin. Rational and timely use is critical in tertiary care hospitals to optimize patient outcomes and conserve resources. This prospective study evaluates cryoprecipitate utilization and appropriateness of transfusion practices and also assesses appropriateness and highlights department-wise variations, seasonal utilization trends, and real-world fibrinogen response, thereby offering a pragmatic insight into transfusion practices in a high-volume Indian tertiary care center. Materials and Methods: A prospective observational study involving 3249 patients (April 2024September 2025) was conducted at Nizams Institute of Medical Sciences. Patients aged 18 years who received cryoprecipitate during CABG, liver transplantation, or massive intraoperative bleeding were included. Data collection included demographics, transfusion episodes, laboratory parameters, and fibrinogen response. Results: A total of 3249 cryoprecipitate units were transfused across 1093 episodes in 951 patients. Cardiothoracic surgery utilized the maximum (47), followed by hematology (38) and surgical gastroenterology (11). Appropriateness was observed in 73 of cases. Mean fibrinogen increase post-transfusion was 25 mgdL (0.25 gL). Seasonal variation was observed, with peak usage during December to January months, suggesting potential links with surgical scheduling or clinical case load trends. Conclusion: Cryoprecipitate usage was largely appropriate (73) but gaps remain. Department-specific trends emphasize the need for stricter adherence to guidelines and individualized transfusion strategies. Continuous medical education, point-of-care monitoring, and algorithm-based transfusion decision-making could optimize utilization.